Barclays Starts Acceleron Pharma (XLRN) at Overweight
Tweet Send to a Friend
Barclays analyst Carter Gould initiates coverage on Acceleron Pharma (NASDAQ: XLRN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


